Study of Oglemilast for the Prevention of Asthma.

Forest Laboratories

Status and phase: Completed; Phase 2

Conditions: Exercise-Induced Asthma

Treatments: Drug: Oglemilast; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00322283

GRC-MD-01

Details and patient eligibility

About

The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.

Enrollment: 24 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• stable mild asthma patients who exhibit at least a 20% decrease in FEV1 following exercise.

Exclusion criteria

• pulmonary disease other than asthma, psychiatric illness, active cardiac disease, high blood pressure, history of substance abuse, current smokers.

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

24 participants in 2 patient groups, including a placebo group

Oglemilast

Experimental group

Treatment:

Drug: Oglemilast

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo